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Editorial Open Access
Bioequivalence & Bioavailability
In a previous editorial, I discussed a cancer research project 
underway and how this may lead to more use of bioequivalence and 
bioavailability in oncology [1]. Recently there has been a development 
and it relates to Omics conferences and breast cancer. 
Permit me an observation. With the advent of open access 
publishing, there seems to be less need to attend distant conferences 
where the typical attendees are high level people who are thought 
leaders in specialized fields. These people frequently publish papers and, 
using modern open access, anyone can download and read their papers 
(Omics has played an important role in promoting open access). Why 
travel to meetings where your peers discuss their published work in 
front of others interested in the same field? You can more conveniently 
and with less stress to your budget read their papers in the comfort of 
your office or home lounge chair.
In comparison, I have attended over 10 Omics conferences. The 
thing I like best about Omics conferences and why I keep going there is 
the opportunity to meet people from other countries and cultures who 
may discuss community based research and might have something of 
interest to say or provide a new perspective or research opportunity. As 
one notable recent example, I was attending an Omics conference in 
Baltimore, MD last October accompanied by my wife. There were 4 or 
5 separate Omics conferences going on concurrently in the same hotel 
and there were many people I did not know. At a lunch break my wife 
and I decided to sit at a table where there were 7 people already present 
who all looked to be Africans. They were the best dressed persons at the 
conference and were attending a hematology-oncology meeting. I did 
not know any of them but my wife who has extremely good social skills 
made sure everyone introduced themselves and got the conversation 
going among us. 
Eventually the conversation got around to the breast cancer 
research I am doing with my colleagues from Italy, Belgium, and 
the UK. I discussed that based on a retrospective study this research 
might result in a low cost and low toxicity intervention that could 
dramatically reduce relapses from early to late stage disease [2]. 
By low cost, I mean a $1.92 drug given once. The problem we have 
encountered is that paradoxically the therapy is too inexpensive. That 
is, it needs to be confirmed in a randomized controlled clinical trial that 
can cost significant funds to conduct but there is no financial reason 
to justify such a trial by a conventional pharmaceutical company. It 
is not that these people are evil. It is just a financial reality. If I were 
working for a pharmaceutical company instead of doing academic 
research I would probably not request management to spend millions 
of dollars to support a project that will show no financial return even if 
scientifically successful. To add to our inability to get financial support, 
as a policy rule the US NIH does not support phase III trials which 
is what is needed. We submitted three grant proposals to support 
confirming clinical trials in India and all were rejected. This may be 
an inexpensive solution to an expensive problem. Absurdity does not 
begin to describe this bizarre situation but it is real [3]. According to 
clinicaltrials.gov there is a small trial underway in Brussels, Belgium 
and another is planned in Seoul, South Korea so there may be results to 
show in upcoming years.
As an unexpected result of my chance encounter at the Baltimore 
Omics conference, I have been invited to a conference in Nigeria. The 
underlying science is that our therapy – perioperative use of a common 
analgesic NSAID in breast cancer surgery - might reduce relapse and 
eventual mortality in breast and other cancers. It is relevant that the 
Nigerian population might be the best possible group to show benefit 
from this therapy. This proposed benefit would appear within 1-3 years 
after primary surgery.  The therapy should work best for triple negative 
breast cancer in which case there is no effective targeted therapy 
indicated. Only adjuvant chemotherapy has shown some value. Triple 
negative is not very common in the US but is more frequently seen in 
other biologically distinct groups especially Koreans, Indians and Sub-
Saharan Africans. A key indicator is the age at diagnosis. Typically the 
type of breast cancer we think should respond best is for women who 
present at an early age – say in their 40s compared to 50s as is most 
often the case in the US [4]. With a large percentage of triple negative 
breast cancer in the Nigerian population, we could determine if there 
is the expected advantage with relatively few patients and in a relatively 
short time. 
This connection is totally the result of unplanned networking at 
the Baltimore 2014 Omics conference. I recommend that you attend 
Omics conferences, acquire social skills, and make an effort to meet 
and speak to people from other parts of the world. I will report more 
after the conference in Nigeria that is scheduled for July 8-12, 2015 in 
Obaju and in Sokoto on July 13. 
Conflicts of Interest
Michael Retsky is on the board of directors of the Colon Cancer 
Alliance, is Chief Scientific Officer at GR Enterprises and Technologies, 
Inc. and has a patent pending for treatment of early stage cancer. No 
other conflicts to report.
References
1. Retsky M (2015) BABE is A Beautiful Science: Why is it Not More Often Used 
in Oncology? J Bioequiv Availab 7:e63. 
2. Retsky M, Demicheli R, Hrushesky WJ, Forget P, De Kock M, et al. (2013) 
Reduction of breast cancer relapses with perioperative non-steroidal anti-
inflammatory drugs: new findings and a review.  Curr Med Chem 20: 4163-
4176.
3. http://www.propublica.org/article/where-are-the-low-cost-cancer-treatments
4. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID, et al. (2007) 
Racial disparities in breast cancer outcome: insights into host-tumor 
interactions. Cancer 110: 1880-1888.
*Corresponding author: Michael Retsky, Harvard T.H. Chan School of Public 
Health, Boston, MA 02115, USA and University College London, UK, Tel: 203-675-
0017; E-mail: michael.retsky@gmail.com
Received May 14, 2015; Accepted May 15, 2015; Published May 22, 2015
Citation: Retsky M (2015) Omics Conferences and Breast Cancer in Sub-Saharan 
Africa. J Bioequiv Availab 7: e66. doi:10.4172/jbb.10000e66
Copyright: © 2015 Retsky M. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
Omics Conferences and Breast Cancer in Sub-Saharan Africa
Retsky M*
Editor in Chief Journal of Bioequivalence and Bioavailability, Harvard TH Chan School of Public Health, USA
